FY23 Corporate Strategy and Sustainability Journey

Core businesses - Generic Markets North America - Growth in 9 out of last 12 quarters Win in channels Retail 60%+ products are ranked 1-3 Institutional 58% + products are ranked 1-3 OTC Private label Ranked 2 in Rx- OTC segment • 190+ commercial products Robust pipeline* of 175+ products, 81 of them filed ~40% Injectables/Sterile products • 25+ complex products • At advanced stages on multiple platform technologies - Particulate Systems, Microsphere & Liposomal, Peptides platform, Emulsions and Suspensions Focus areas Horizon-1 - Injectables, retail generics productivity, OTC & direct to patients Horizon-2 - Biosimilars, digital solutions, drug-device combos & immune oncology Europe -21% sales CAGR in last four years Continuous Growth & expansion • New countries Strong pipeline* of biosimilars and generics • Focus areas 5 added in the last year 185 Commercial products Source: Internal analysis, IQVIA *Pipeline means products filed or in under development stage or approved but yet to be launched Horizon-1 - Build scale in EU5 (Germany, UK, Spain, France & Italy), selective expansion to other markets & first to market launches Horizon-2 - Branded businesses (Differentiated branded & OTC), New spaces (Pharmaceutical Cannabis) & Biosimilars 17 © copyright Dr. Reddy's Ltd.

View entire presentation